Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19434539 | 0.84 | NPSR1 (0.50) | NPC1NPSR1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2175952 | 0.80 | NPC1 (0.44) | NPC1NPSR1KDM4EMAPK1ATM | |
| SCHEMBL2176691 | 0.76 | LOXL2 (0.44) | NPC1NPSR1KDM4EMAPK1ATM | |
| SCHEMBL19434614 | 0.75 | L3MBTL1 (0.38) | NPC1L3MBTL1ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL69407 | 0.74 | KDM4E (0.53) | NPC1NPSR1KDM4EMAPK1ATM | |
| SCHEMBL19434672 | 0.72 | MEN1 (0.41) | NPC1MAPK1L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1627925 | 0.71 | CYP4A11 (0.60) | NPC1KDM4EMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL19434537 | 0.70 | NPSR1 (0.47) | NPC1NPSR1MAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL21448919 | 0.70 | NPC1 (0.46) | NPC1NPSR1KDM4EMAPK1ATM | |
| SCHEMBL21538909 | 0.69 | CXCL8 (0.36) | CXCL8AKR1B1PTGS1PTGS2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440073-B1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LTD (GB) | 2022-06-08 | — | — | EP | disclosed |
| US-10442828-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| EP-3440073-A1 | KINASE INHIBITORS | Topivert Pharma Limited (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-20180305383-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-10-25 | — | — | US | disclosed |
| US-10072034-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2018-09-11 | — | — | US | disclosed |
| US-20170291917-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| WO-2017174995-A1 | KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072034-B2 | Kinase inhibitors | SYK, LYN, BTK | NPC1 4825/4885NPSR1 1649/4885KDM4E 2053/4885 |
| US-20180305383-A1 | KINASE INHIBITORS | SYK, LTK, LTB4R | NPC1 4645/4885NPSR1 1074/4885KDM4E 2216/4885 |
| US-10442828-B2 | Kinase inhibitors | SYK, LTK, LTB4R | NPC1 4645/4885NPSR1 1074/4885KDM4E 2216/4885 |
| US-20170291917-A1 | KINASE INHIBITORS | SYK, LYN, BTK | NPC1 4825/4885NPSR1 1649/4885KDM4E 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.